Our study demonstrates the sensitivity of ES cells
to chronic hypoxia in the context of the dephosphorylation of ERK and Akt with the possible involvement of ROS-dependent mechanisms.
Although there is no published record of ES cell
research in Oman, stem cell transplantation (bone marrow, peripheral blood, and cord blood) has been carried out at Sultan Qaboos University Hospital (SQUH) since 1995.5 More recently, researchers at SQUH established the first national voluntary cord blood bank in the country.
We hypothesized that if angioblast-like cells could be obtained from iPS or ES cells
, these cells would operate like EPCs and restore numerous impairments in DPN.
STORAGE OF IPSCS: Cryopreservation is a critical step in the storage and transportation of human embryonic stem cells (ES cells
) and induced pluripotent stem cells (iPS cells).
Through technology license agreement with San Diego Regenerative Medicine Institute, Xcelthera Inc has become the first in the world to hold the proprietary breakthrough technology for large-scale production of high quality clinical-grade pluripotent human ES cell
lines and their functional human neuronal and heart cell therapy products for commercial and therapeutic uses.
These cells demonstrated their renewal capabilities, which is one of the characteristics of ES cell
We sought next to test the hypothesis that TET2 expression promotes ES cell
In humans, mutations in 25 different homeobox transcription factors have been found in patients with congenital heart disease (McCulley and Black 2012); expression of 14 of these (Cited2, Ets1, Foxh1, Gata4, Gata6, Handl, Hand2, Hoxal, Irxl, Nkx2-5, Nkx2-6, Pitx2, and Tbx1) was disrupted by TCDD in our mouse ES cell
Quantification of IGF-1R in ES Cell
Lines and Patient Tumors.
The safety of their use has not been proven unequivocally and there are concerns that these 'old' re-programmed somatic cells may not behave identically to their 'young' ES cell
ESI-035, ESI-049, ESI-051 and ESI-053 were developed by ES Cell
International Pte Ltd, a wholly owned subsidiary of BioTime.
medium was composed of KnockoutTM high glucose DMEM (Invitrogen) supplemented with 11.25% KSR (vol/vol) (Invitrogen), 3.75% FBS (vol/vol) (Hyclone), 20 ng/ml leukemia inhibitory factor (LIF) (Chemicon), 1mM nonessential amino acids (NEAA) (Invitrogen) and 0.1 mM P-mercaptoethanol (Sigma).